NASTAD Releases Updated 2019 ADAP Formulary Database

By: Tim Horn, Director, Medication Access and Pricing, NASTAD

The National Alliance of State & Territorial AIDS Directors ("NASTAD") has released an updated 2019 Online AIDS Drug Assistance Program ("ADAP") Formulary Database ("the Database"), which may be accessed via the accompanying User’s Guide. The Database provides an online, searchable, publicly available resource detailing state-by-state ADAP coverage of medications both individually and by drug class including HIV antiretroviral (ARV) treatments, “A1” Opportunistic Infections (A1 "OI") medications, treatments for hepatitis B and C, mental health and substance use treatment medications, and various vaccines and laboratory tests and includes ADAP formulary coverage for all 50 states, the District of Columbia, Guam, Puerto Rico, and the U.S. Virgin Islands as of December 31, 2018.

 Key findings from the updated 2019 ADAP Formulary Database include:

• 11 ADAPs have “open formularies” in which all FDA-approved medications are included, excluding designated exceptions
• 42 ADAPs cover one or more hepatitis B treatment medication
• 41 ADAPs cover one or more hepatitis C treatment medication
• 39 ADAPs cover one or more of the curative direct acting antiviral ("DAA") hepatitis C ("HCV") treatment medications
• 27 cover daclatasvir (Daklinza)
• 35 cover elbasvir and grazoprevir (Zepatier)
• 36 cover glecaprevir and pibrentasvir (Mavyret)
• 33 cover ledipasvir and sofosbuvir (Harvoni)
• 30 cover sofosbuvir (Sovaldi)
• 31 cover sofosbuvir, velpatasvir (Epclusa)
• 22 cover sofosbuvir, velpatasvir, and voxilaprevir (Vosevi)
• 48 ADAPs cover one or more of the most frequently prescribed mental health treatment medications
• 30 ADAPs cover one or more substance use treatment medication

NASTAD thanks state ADAP coordinators who provided the important data that comprises the ADAP Formulary Database. Questions regarding the Database may be directed to Amanda Bowes, Manager, Health Care Access.